OVID
Ovid Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.69
−0.37%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.08
- Revenue estimate
- $17.8K
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.08
- EPS estimate
- -$0.12
- Revenue actual
- $733.0K
- Revenue estimate
- $21.4K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +42.1%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $7.00
- PT range
- $5.00 – $9.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.12 | -$0.08 | Beat 30.43% | $733.0K |
| May 12, 2026 | -$0.12 | -$0.12 | In line | — |
| Mar 18, 2026 | -$0.12 | $0.06 | Beat 151.25% | $718.0K |
| Nov 12, 2025 | -$0.15 | -$0.17 | Miss -13.33% | $132.0K |
| Aug 13, 2025 | -$0.16 | -$0.06 | Beat 62.50% | — |
| Mar 11, 2025 | -$0.16 | -$0.13 | Beat 18.75% | $76.0K |
| May 14, 2024 | -$0.23 | -$0.17 | Beat 26.09% | $148.0K |
| Mar 8, 2024 | -$0.17 | -$0.22 | Miss -29.41% | $141.6K |
| Nov 3, 2023 | -$0.18 | -$0.16 | Beat 11.11% | $109.0K |
| Aug 4, 2023 | -$0.21 | -$0.18 | Beat 14.29% | $75.0K |
| May 5, 2023 | -$0.18 | -$0.19 | Miss -5.56% | $66.0K |
| Mar 13, 2023 | -$0.19 | -$0.16 | Beat 15.79% | $46.3K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026